Alnylam Pharmaceuticals, Inc. (ALNY) presented KARDIA-2 Phase 2 study results of zilebesiran for the treatment of hypertension at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
The study met the primary endpoint showing that zilebesiran resulted in clinically significant additive, placebo-adjusted reductions in 24-hour mean systolic blood pressure (SBP) at Month 3 when Zilebesiran was added to a diuretic, calcium-channel blocker or angiotensin receptor blocker.
The company stated that the Zilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives and the study results support potential for biannual dosing of Zilebesiran.
Alnylam Pharma specified that full study results to be presented as a late-breaking clinical trial at the 2024 American College of Cardiology Annual Scientific Session on April 7.
Alnylam and Roche also announced the initiation of the KARDIA-3 Phase 2 study in adult patients with high cardiovascular risk and uncontrolled hypertension despite treatment with standard of care antihypertensive medications.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.